Bank of New York Mellon Corp - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$421,096
-16.3%
356,8610.0%0.00%
Q2 2023$503,173
+373.6%
356,861
+403.8%
0.00%
Q1 2023$106,242
+28.2%
70,8280.0%0.00%
Q4 2022$82,868
+3.6%
70,828
+0.0%
0.00%
Q3 2022$80,000
-28.6%
70,8270.0%0.00%
Q2 2022$112,000
-82.3%
70,827
-82.8%
0.00%
Q1 2022$633,000
-38.7%
410,895
-2.5%
0.00%
Q4 2021$1,032,000
-3.6%
421,244
-0.9%
0.00%
Q3 2021$1,071,000
-1.5%
425,009
+11.5%
0.00%
Q2 2021$1,087,000
+535.7%
381,215
+422.9%
0.00%
Q1 2021$171,000
+18.8%
72,899
-10.9%
0.00%
Q4 2020$144,000
+94.6%
81,825
+3.7%
0.00%
Q3 2020$74,000
+7.2%
78,8850.0%0.00%
Q2 2020$69,000
-79.7%
78,885
-80.8%
0.00%
Q1 2020$340,000
-22.9%
410,485
-17.2%
0.00%
Q4 2019$441,000
-1.3%
495,777
+8.8%
0.00%
Q3 2019$447,000455,7230.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders